BeStock  

ResMed RMD

US equityMarket cap rank #420Medical Instruments & Supplies
$222.87 +$1.77 (+0.80%)
Market open · Oct 1, 11:50 am ET · After hours $221.10 0.00%
Open$220.19
Prev close$221.10
Day range$219.00 – $224.14
Volume255.9K
Market cap$32.15B
P/E (TTM)21.4
Dividend yield1.08%

Fundamentals

Latest reported quarter: Q4, ended Jun 2026

Revenue$1.46B+8.6% YoY
Operating profit$448.71M-1.3% YoY
Net profit$383.43M+1.0% YoY
Diluted EPS$2.64+2.3% YoY
Free cash flow$397.38M-21.3% YoY
Operating cash flow$454.63M

Revenue, last 8 quarters

$1.2BSep '24$1.3BDec '24$1.3BMar '25$1.3BJun '25$1.3BSep '25$1.4BDec '25$1.4BMar '26$1.5BJun '26

Net profit, last 8 quarters

$311.4MSep '24$344.6MDec '24$365.0MMar '25$379.7MJun '25$348.5MSep '25$392.6MDec '25$398.7MMar '26$383.4MJun '26

Diluted EPS by quarter

2.11Sep '242.34Dec '242.48Mar '252.58Jun '252.37Sep '252.68Dec '252.74Mar '262.64Jun '26

Free cash flow by quarter

$305.9MSep '24$285.2MDec '24$554.9MMar '25$505.0MJun '25$411.5MSep '25$305.2MDec '25$514.5MMar '26$397.4MJun '26

Annual revenue

$3.2BFY21$3.6BFY22$4.2BFY23$4.7BFY24$5.1BFY25$5.7BFY26

Profitability & balance sheet

Gross margin61.1%
Operating margin33.8%
Net margin26.9%
Return on equity24.3%
Return on assets17.8%
Return on invested capital21.4%
Current ratio3.10
Liabilities / assets26.6%
Cash & investments$1.47B
Total debt$796.78M
Net cash (debt)$672.46M
Free cash flow / sales28.8%

Income statement

Line item 2026 ANNUAL 2026 Q4 2026 Q3 2026 Q2 2026 Q1
Total Revenue as Reported $5.65B $1.46B $1.43B $1.42B $1.34B
Total Operating Revenue $5.65B $1.46B $1.43B $1.42B $1.34B
Cost of Revenue $2.20B $602.43M $540.43M $544.08M $514.76M
Gross Profit $3.45B $861.22M $890.98M $878.72M $820.82M
Operating Expense $1.54B $412.51M $391.17M $381.13M $358.47M
Selling and Admin Expenses $1.12B $296.28M $285.66M $278.40M $259.19M
Research & Development $378.29M $105.73M $94.27M $90.97M $87.32M
Depreciation & Amortization & Depletion $45.47M $10.50M $11.25M $11.76M $11.96M
-Depreciation & Amortization $45.47M $10.50M $11.25M $11.76M $11.96M
Operating Profit $1.91B $448.71M $499.81M $497.60M $462.35M
Net Non-Operating Interest Income (Expense) $49.91M $20.89M $12.29M $7.95M $8.79M
Total Other Finance Costs -$49.91M -$20.89M -$12.29M -$7.95M -$8.79M
Other Income (Expense) -$38.96M $4.57M -$9.79M -$9.40M -$24.35M
Earnings from Equity Interest -$8.06M $3.23M -$8.41M $1.82M -$4.70M
Special Income (Charges) -$21.75M $0.00 $0.00 -$5.94M -$15.81M
-Less:Restructuring and Mergern & Acquisition $21.75M $0.00 $0.00 $5.94M $15.81M
Other Non-Operating Income (Expenses) -$9.15M $1.33M -$1.37M -$5.28M -$3.84M
Pretax Profit $1.92B $474.16M $502.31M $496.15M $446.79M
Tax $396.12M $90.73M $103.58M $103.56M $98.26M
Net Profit $1.52B $383.43M $398.73M $392.59M $348.54M
Profit from Continuing Operations $1.52B $383.43M $398.73M $392.59M $348.54M
Net Income to Parent Company $1.52B $383.43M $398.73M $392.59M $348.54M
Net Income to Common Stockholders $1.52B $383.43M $398.73M $392.59M $348.54M
Basic EPS $10.47 $2.65 $2.74 $2.69 $2.38
Diluted EPS $10.43 $2.64 $2.74 $2.68 $2.37
Dividend Per Share $2.40 $0.60 $0.60 $0.60 $0.60

Balance sheet

Line item 2026 ANNUAL 2026 Q4 2026 Q3 2026 Q2 2026 Q1
Total Assets $8.97B $8.97B $8.78B $8.50B $8.31B
Total Current Assets $4.32B $4.32B $4.06B $3.82B $3.63B
Cash and Cash Equivalents & Short-Term Investments $1.47B $1.47B $1.66B $1.42B $1.38B
-Cash and Cash Equivalents $1.47B $1.47B $1.66B $1.42B $1.38B
Receivables $1.08B $1.08B $1.05B $1.05B $958.42M
-Accounts Receivable $1.04B $1.04B $998.84M $985.63M $907.27M
-Other Receivables $48.72M $48.72M $47.11M $61.41M $51.15M
Prepaid Assets $182.00M $182.00M $254.83M $252.70M $177.00M
Inventory $945.81M $945.81M $911.88M $922.05M $945.81M
Other Current Assets $185.36M $185.36M $190.90M $179.94M $160.67M
Total Non-Current Assets $4.64B $4.64B $4.72B $4.68B $4.68B
Net PPE $735.00M $735.00M $728.57M $730.17M $725.64M
-Gross PPE $1.49B $1.49B $1.51B $1.48B $1.45B
-Accumulated Depreciation -$751.00M -$751.00M -$779.25M -$747.96M -$723.04M
Goodwill and Other Intangible Assets $3.36B $3.36B $3.47B $3.47B $3.49B
-Goodwill $2.91B $2.91B $3.04B $3.04B $3.04B
-Other Intangible Assets $452.74M $452.74M $425.19M $430.24M $447.07M
Non-Current Deferred Assets $329.25M $329.25M $312.59M $285.91M $275.95M
Other Non-Current Assets $214.65M $214.65M $210.73M $193.88M $189.84M
Total Liabilities $2.38B $2.38B $2.29B $2.18B $2.19B
Total Current Liabilities $1.40B $1.40B $1.35B $1.25B $1.26B
Payables $447.60M $447.60M $436.62M $390.90M $402.02M
-Accounts Payable $308.92M $308.92M $273.30M $250.41M $266.78M
-Total Tax Payable $138.67M $138.67M $163.32M $140.49M $135.24M
Current Accrued Expenses $437.71M $437.71M $446.15M $391.50M $395.83M
Short-Term Debt and Capital Lease Obligation $289.09M $289.09M $289.16M $289.67M $289.87M
-Current Debt $259.95M $259.95M $259.93M $259.91M $259.90M
-Current Capital Lease Obligation $29.14M $29.14M $29.23M $29.76M $29.98M
Current Deferred Liabilities $162.91M $162.91M $179.28M $176.05M $167.78M
Other Current Liabilities $57.80M $57.80M – – –
Total Non-Current Liabilities $985.45M $985.45M $941.16M $934.38M $931.59M
Long Term Debt and Capital Lease Obligation $536.83M $536.83M $554.01M $558.06M $556.48M
-Long Term Debt $399.42M $399.42M $404.17M $403.92M $408.66M
-Long Term Capital Lease Obligation $137.41M $137.41M $149.84M $154.13M $147.82M
Non-Current Deferred Liabilities $235.59M $235.59M $241.08M $237.78M $236.93M
Other Non-Current Liabilities $213.03M $213.03M $146.08M $138.54M $138.18M
Total Equity $6.59B $6.59B $6.49B $6.32B $6.12B
Stockholders' Equity $6.59B $6.59B $6.49B $6.32B $6.12B
Capital Stock $764,000.00 $764,000.00 $763,000.00 $763,000.00 $762,000.00
-Common Stock $764,000.00 $764,000.00 $763,000.00 $763,000.00 $762,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $2.19B $2.19B $2.13B $2.10B $2.06B
Retained Earnings $7.26B $7.26B $6.96B $6.65B $6.34B
Less: Treasury Stock $2.78B $2.78B $2.58B $2.40B $2.22B
Gains/Losses Not Affecting Retained Earnings -$82.52M -$82.52M -$24.91M -$29.86M -$60.72M

Cash flow

Line item 2026 ANNUAL 2026 Q4 2026 Q3 2026 Q2 2026 Q1
Operating Cash Flow $1.81B $454.63M $554.13M $339.75M $457.32M
Net cash flow from continuing operations $1.81B $454.63M $554.13M $339.75M $457.32M
Net Income from Continuing Operations $1.52B $383.43M $398.73M $392.59M $348.54M
Gain/Loss from Continuing Operations $8.28M -$3.01M $8.41M -$1.82M $4.70M
Depreciation & Depletion & Amortization $244.15M $55.12M $69.03M $62.33M $57.67M
Change in Working Capital -$74.24M -$8.37M $51.16M -$142.30M $25.26M
-Change in Receivables -$96.78M -$37.21M -$16.86M -$72.68M $29.97M
-Change in Inventory -$9.92M -$33.87M $12.48M $26.13M -$14.66M
-Change in Prepaid Assets -$140.26M $12.15M -$48.34M -$106.39M $2.31M
-Change in Payables and Accrued Expense $172.72M $50.56M $103.88M $10.65M $7.64M
Net cash flow from investing -$545.20M -$383.65M -$58.03M -$50.94M -$52.58M
Net Cash Flow from Continuing Investing Activities -$545.20M -$383.65M -$58.03M -$50.94M -$52.58M
Net PPE Purchase and Sale -$156.29M -$51.13M -$33.65M -$28.54M -$42.97M
Net Intangibles Purchase and Sale -$20.89M -$6.12M -$5.94M -$6.02M -$2.81M
Net Business Purchase and Sale -$350.72M -$325.32M -$24.88M $0.00 -$522,000.00
Net Investment Purchase and Sale -$17.30M -$1.08M $6.44M -$16.39M -$6.28M
Financing Cash Flow -$1.01B -$263.16M -$255.24M -$258.35M -$230.27M
Net Cash Flow from Continuing Financing Activities -$1.01B -$263.16M -$255.24M -$258.35M -$230.27M
Net Issuance Payments Of Debt -$10.00M -$5.00M $0.00 -$5.00M $0.00
Net Common Stock Issuance -$625.53M -$170.69M -$167.59M -$145.46M -$141.81M
Cash Dividends Paid -$349.66M -$87.09M -$87.24M -$87.58M -$87.75M
Net Other Financing Charges -$21.83M -$388,000.00 -$418,000.00 -$20.31M -$719,000.00
Ending Cash Balance $1.47B $1.47B $1.66B $1.42B $1.38B
Net Change in Cash $253.60M -$192.18M $240.86M $30.45M $174.47M
Beginning Cash Balance $1.21B $1.66B $1.42B $1.38B $1.21B
Effect of Exchange Rate Changes $6.18M $905,000.00 $2.58M $2.77M -$71,000.00
Free Cash Flow $1.63B $397.38M $514.54M $305.19M $411.54M

Discussion

No comments yet — be the first to weigh in on RMD.

Leave a comment

Scroll to Top